Related Experiment Videos
Synergy between CD28 and CD9 costimulation for naive T-cell activation
K Toyo-oka1, X G Tai, Y Yashiro
1Biomedical Research Center, Osaka University Medical School, Japan.
Immunology Letters
|June 1, 1997
Summary
CD9 and CD28 provide distinct costimulatory signals for T-cell activation. Combining CD9 and CD28 signals synergistically enhances T-cell responses, indicating different signaling pathways are involved.
Area of Science:
- Immunology
- Cellular Biology
- Molecular Signaling
Background:
- Previous research established CD9 as a costimulatory molecule on naive T-cells, functioning independently of CD28.
- The precise nature of CD9-mediated costimulation and its relationship with CD28 signaling remained unclear.
Purpose of the Study:
- To elucidate the differences between CD9 and CD28 costimulatory signals.
- To investigate the synergistic potential of combined CD9 and CD28 signaling in T-cell activation.
Main Methods:
- Naive T-cells were stimulated with anti-CD3 monoclonal antibody (mAb) in combination with co-immobilized or soluble anti-CD9 or anti-CD28 mAbs.
- T-cell activation was assessed by [3H]TdR incorporation and lymphokine production (IL-2, IFN-gamma).
- Experiments also utilized phorbol myristate acetate (PMA) to further differentiate signaling pathways.
Main Results:
- Both anti-CD9 and anti-CD28 mAbs, when co-immobilized with anti-CD3, similarly enhanced T-cell proliferation.
- Soluble anti-CD28 mAb costimulated T-cells, but soluble anti-CD9 mAb did not, highlighting pathway differences.
- Combined stimulation with anti-CD9 and anti-CD28 mAbs resulted in significantly enhanced T-cell proliferation and lymphokine production compared to individual costimulation.
Conclusions:
- CD9 and CD28 utilize distinct signaling pathways for T-cell costimulation.
- The combination of CD9 and CD28 signaling leads to synergistic T-cell activation, offering a novel therapeutic target.